Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.
Shanghai Henlius Biotech has entered into an exclusive licensing agreement with Insud Pharma’s Mabxience Research to develop and commercialize the Chinese firm’s HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay. Financial and other terms of the deal were not disclosed.
Noting that its trastuzumab had been developed and manufactured “in accordance with international standards,” Henlius added that it was China’s...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
